AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial

AtriCure has announced the successful treatment of the first patient in their BoxX-NoAF clinical trial. This pivotal trial is set to evaluate the safety and effectiveness of the AtriCure Isolator® Synergy™. The procedure, which marks a significant step for AtriCure, was performed as part of an ongoing effort to assess the innovative capabilities of this device. The trial aims to focus on providing insights into the therapy's performance and potential benefits for patients under real-world conditions. Such advancements underscore AtriCure’s commitment to pioneering cardiac solutions and improving patient outcomes.\n\n